Monotherapy or combination therapy for fibromyalgia treatment

Current Rheumatology Reports

Volumn 14, Issue 6, 2012, Pages 568-575

  Calandre, Elena Pita ^a   Rico Villademoros, Fernando ^a   Rodríguez López, Carmen María ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF ALMERÍA   (Spain)

Author keywords

Combination therapy; Fatigue; Fibromyalgia; Monotherapy; Morning stiffness; Sleep disturbances; Symptomatological diversity; Treatment

Indexed keywords

ALPHA INTERFERON; ALPRAZOLAM; AMITRIPTYLINE; CAFFEINE; CARISOPRODOL; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; IBUPROFEN; MELATONIN; MILNACIPRAN; NAPROXEN; OXYBATE SODIUM; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; TRAMADOL; TRAZODONE;

ANXIETY DISORDER; ARTICLE; BLURRED VISION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DISEASE SEVERITY; DISTRESS SYNDROME; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; EXERCISE; FATIGUE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERHIDROSIS; INDIVIDUALIZATION; INSOMNIA; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); METHODOLOGY; MORNING STIFFNESS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOM; TACHYCARDIA; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

ANALGESICS; ANTIDEPRESSIVE AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FIBROMYALGIA; HUMANS;

EID: 84869218681     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0278-y     Document Type: Article

References (55)

1. Ablin JN, Buskila D, Van Houdenhove B, et al. Is fibromyalgia a discrete entity? Autoimmun Rev. 2012; 11: 585-8.
2. Guymer EK, Clauw DJ. Treatment of fatigue in fibromyalgia. Rheum Dis Clin N Am. 2002; 28: 367-78. (Pubitemid 34733190)
3. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008; 73: 114-20.
4. Humprey L, Arbuckle R, Mease P, et al. Fatigue in fibromyalgia: a conceptual model informed by patients interviews. BMC Musculoskelet Disord. 2010; 11: 216.
5. Finan PH, Zautra AJ. Fibromyalgia and fatigue: central processing, widespread dysfunction. PM & R. 2010; 2: 431-7.
6. Hä userW, Klose P, Langhorst J, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: A systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010; 12: R79.
7. Moldofsky H. The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr. 2008; 13: 22-6. (Pubitemid 351532440)
8. Spaeth M, Rizzi M, Sarzi-Puttini P. Fibromyalgia and sleep. Best Pract Res Clin Rheumatol. 2011; 25: 227-39.
9. Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother. 2011; 12: 1789-98.
10. Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,569 people with fibromyalgia. BMC Musculoskelet Disord. 2007; 8: 27.
11. Bennett R, Russell IJ, Choy E, et al. Evaluation of patientrated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine. Clin Ther. 2012; 34: 824-37.
12. Bellamy, Sothern RB, Campbell J. Aspects of diurnal rhythmicity in pain, stiffness, and fatigue in patients with fibromyalgia. J Rheumatol. 2004; 31: 379-89. (Pubitemid 38160762)
13. Bennett RM, Bushmakin AG, Cappelleri JC, et al. Minimal clinically important difference in the Fibromyalgia Impact Questionnaire. J Rheumatol. 2009; 36: 1304-11.
14. Russell IJ, Michalek JE, Yang YK, et al. Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low-dose of human interferon-alpha. J Interferon Cytokine Res. 1999; 19: 961-8. (Pubitemid 29406653)
15. Glass J. Review of cognitive dysfunction in fibromyalgia: a convergence on working memory and attentional control impairments. Rheum Dis Clin N Am. 2009; 35: 299-311.
16. Munguí a-Izquierdo D, Legaz-Arrese A. Exercise in warm water decreases pain and improves cognitive function in middle-aged women with fibromyalgia. Clin Exp Rheumatol. 2007; 25: 823-30. (Pubitemid 351166432)
17. Arnold LM, Leon T, Whalen E, et al. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia. Psychosomatics. 2010; 51: 489-97.
18. Kurtze N, Gundersen KT, Svebak S. The role of anxiety and depression in fatigue and patterns of pain among subgroups of fibromyalgia patients. Br J Med Psychol. 1998; 71: 185-94.
19. Alok R, Das SK, Agarwal GG, et al. Relationship of severity of depression, anxiety and stress with severity of fibromyalgia. Clin Exp Rheumatol. 2011; 29(6 Suppl 69): S70-2.
20. Jensen KB, Petzke F, Carville S, et al. Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain. Arthritis Rheum. 2010; 62: 3488-95.
21. Pae CU, Masand PS, Marks DM, et al. History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Progr Neuropsychopharmacol Biol Psychiatry. 2009; 33: 996-1002.
22. Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome. Pain in adults and in children. APS Clinical Practice Guideline Series no 4. Glenview: American Pain Society; 2005.
23. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidencebased recomendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008; 67: 536-41. (Pubitemid 351498437)
24. Mease PJ, Seymour K. Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy? Curr Pain Headache Rep. 2008; 12: 399-405. This article accurately describes the different symptom domains of fibromyalgia and details the rationale of using drugs in combination.
25. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997; 40: 1560-70. (Pubitemid 27426148)
26. White KP, NielsonWR, HarthM, et al. Does the label " fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum. 2002; 47: 260-5. (Pubitemid 34627693)
27. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010; 62: 600-10. This article details the new ACR proposal to more accurately diagnose fibromyalgia.
28. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004; 51: 9-13. (Pubitemid 38222276)
29. Hä user W, Bernardy K, Ü ceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. JAMA. 2009; 301: 198-209.
30. Hä user W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome. J Pain. 2010; 11: 505-21.
31. Hä user W, Petzke F, Ü ç eyler N, et al. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford). 2011; 50: 532-43.
32. Roskell NS, Beard SM, Zhao Y, et al. Ameta-analysis of pain response in the treatment of fibromyalgia. Pain Pract. 2011; 11: 516-27.
33. Nishishinya B, Urrú tia G, Walitt B, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford). 2008; 47: 1741-6.
34. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986; 29: 1371-7. (Pubitemid 17214038)
35. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol. 2011; 25: 285-97. An excellent and updated review of the pharmacological treatment of fibromyalgia, which includes some comments concerning combination treatments.
36. Vaerø y H, Abrahamsen A, Fø rre Ø, et al. Treatment of fibromyalgia (fibrositis symdrome): a parallel double-blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clin Rheumatol. 1989; 8: 245-50. (Pubitemid 20122951)
37. Russell IJ, Fletcher EM, Michalek JE, et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. Arthritis Rheum. 1991; 34: 552-60.
38. Fossaluza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res. 1992; 12: 99-102.
39. Cantini F, Bellandi F, Niccoli L, et al. Fluoxetina associata a ciclobenzaprina nel trattamento della fibromialgia. Minerva Med. 1994; 85: 97-100. (Pubitemid 24180133)
40. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyiline in the treatment of fibromyalgia. Arthritis Rheum. 1996; 39: 1852-9. (Pubitemid 26378576)
41. Bennett RM, Kamin M, Karim R, et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003; 114: 537-45. (Pubitemid 36577256)
42. Calandre EP, Morillas-Arques P, Rodriguez-Lopez CM, et al. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry. 2007; 40: 68-71. (Pubitemid 46697677)
43. Calandre EP, Morillas-Arques P, Molina-Barea R, et al. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskelet Disord. 2011; 12: 95.
44. Hussain SA, Al-Khalifa II, Jasim NA, et al. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res. 2011; 50: 267-71.
45. Kim SH, Song J, Mun H, et al. Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia. Korean J Intern Med. 2009; 24: 139-42.
46. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003; 48: 2916-22. (Pubitemid 37280621)
47. Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology. 1997; 55: 235-43. (Pubitemid 27472695)
48. Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs. 2008; 68: 2611-32.
49. Wang RW, Liu L, Cheng H. Identification of human liver P-450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996; 24: 786-91. (Pubitemid 26244222)
50. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004; 26: 1355-67. (Pubitemid 39572151)
51. Scholz BA, Hammonds CL, Boomershine CS. Duloxetine for the management of fibromyalgia syndrome. J Pain Res. 2009; 2: 99-108.
52. Ormseth MJ, Eyler AE, Hammonds CL, et al. Milnacipran for the management of fibromyalgia syndrome. J Pain Res. 2010; 3: 15-24.
53. Boomershine CS. Pregabalin for the management of fibromyalgia syndrome. J Pain Res. 2010; 3: 81-8.
54. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs. 2012; 26: 135-53.
55. Hä user W, Bernardy K, Arnold B, et al. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum. 2009; 61: 216-24.